U.S. markets open in 3 hours 13 minutes

Vitality Biopharma, Inc. (VBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4200+0.0100 (+2.44%)
At close: 3:54PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4100
Open0.4000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4000 - 0.4299
52 Week Range0.0500 - 1.6100
Volume15,360
Avg. Volume114,274
Market Cap21.294M
Beta (5Y Monthly)3.86
PE Ratio (TTM)N/A
EPS (TTM)-0.0150
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • VITALITY BIOPHARMA INC
    Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.
    Rating
    Fair Value
    Economic Moat
    29 days agoMorningstar
View more
  • GlobeNewswire

    Vitality Biopharma Announces Effective S-1 Registration Statement and DTC Eligibility

    CLEVELAND, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC Mkts: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic powers of cannabinoids, today announced that the Securities and Exchange Commission has declared the Company’s Form S-1 registration statement effective. The registration statement was filed pursuant to the Securities Purchase Agreement, dated as of August 19, 2021, entered into by the Company w

  • GlobeNewswire

    Vitality Biopharma Enters Into $5 Million Equity Line Financing Relationship With Institutional Investor

    CLEVELAND, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic powers of cannabinoids, today announced that the Company had entered into a definitive agreement with an institutional investor for a $5,000,000 equity line financing. Under the terms of the equity line financing, once the registration statement covering these shares is declared effective, the institutiona

  • GlobeNewswire

    FDA Grants Vitality Biopharma Orphan Drug Designation for VBX-100 Prodrug

    CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic powers of cannabinoids, today announced that the U.S. Food and Drug Administration (“FDA”) granted Orphan Drug Designation to its glycosylated cannabinoid prodrug VBX-100 for the treatment of pediatric ulcerative colitis. “The FDA’s granting of Orphan Drug Designation for VBX-100, our leading glycosyl